Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsMEDIF +7.20% Equity-to-Asset is 0.77 as of Jun. 2026, which is 5% below its 10-year median of 0.81. The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, MediPharm Labs ranks better than 76.29% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MediPharm Labs's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $25.25 Mil. MediPharm Labs's Total Assets for the quarter that ended in Jun. 2026 was $32.77 Mil.
Therefore, MediPharm Labs's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.77.
The historical rank and industry rank for MediPharm Labs's Equity-to-Asset or its related term are showing as below:
MEDIF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49 Med: 0.81 Max: 1
Current: 0.77
During the past 9 years, the highest Equity to Asset Ratio of MediPharm Labs was 1.00. The lowest was 0.49. And the median was 0.81.
MEDIF's Equity-to-Asset is ranked better than 76.29% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs MEDIF: 0.77
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MediPharm Labs Equity-to-Asset Related Terms
MediPharm Labs Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
MediPharm Labs's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (MEDIF) has a Equity-to-Asset of 0.77 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MediPharm Labs and its competitors. This is near median its historical median of 0.81. Over the past decade, MediPharm Labs' Equity-to-Asset has ranged from 0.49 to 1.00. According to the industry distribution chart, MediPharm Labs ranks #239 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is MediPharm Labs' Equity-to-Asset too high?
MediPharm Labs' current Equity-to-Asset of 0.77 is near median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 1.00. The Drug Manufacturers industry median Equity-to-Asset is 0.60. MediPharm Labs' value of 0.77 is 28.3% above this industry median. Based on the distribution chart, MediPharm Labs ranks #239 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #239 out of 1008 companies for Equity-to-Asset. This places MediPharm Labs in the top 24% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. MediPharm Labs' value of 0.77 is 28.3% above this benchmark. Historically, MediPharm Labs' own Equity-to-Asset has ranged from 0.49 to 1.00 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 0.60, MediPharm Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Equity-to-Asset of 0.77 is 28.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Equity-to-Asset is 0.77, which is near median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (MEDIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.06 — trading 13.2% above its estimated fair value. The current Equity-to-Asset is 0.77, which is near median its 10-year median of 0.81 and 28.3% above the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MediPharm Labs (MEDIF), the current Equity-to-Asset is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDIF has been successfully added to your 
